Industry Satellite Symposia webcasts #ESMOBREAST2024

Watch the webcasts from our industry partners' Satellite Symposia.

Welcome and introduction
Richard Finn
The current and future treatment landscape for ER+/HER2- metastatic breast cancer setting
Renate Haidinger
An encompassing journey: Shaping clinical decisions
Richard Finn
A unique journey: Personalising approaches
Antonio Llombart Cussac
Panel discussion and audience Q&A
All Speakers
Closing remarks
Wolfgang Janni

Welcome
Sara Tolaney
Reading the chessboard: Transformation and opportunities in the treatment landscape of HER2+ MBC
Sara Tolaney
CNS defence: A case-based conversation about the threat of CNS involvement and clinical decision-making in HER2+ MBC
Rupert Bartsch
Moving forward: A case-based conversation on clinical decision-making in 3L post T-DXd progression and future directions in HER2+ MBC
Carmen Criscitiello
Panel discussion and audience Q&A
All Speakers
Closing remarks
Sara Tolaney

Welcome and introduction
Javier Cortés
Debate topic: How would you sequence ADCs for patients with pretreated HR+/HER2- metastatic breast cancer?
Diana Lüftner
Debate topic: What should be the standard of care treatment for patients with 2L mTNBC?
Sara Tolaney
Q&A / discussion
All Faculty

Welcome, introduction, and goal setting
Stephen Johnston
Conducting risk assessment in HR+, HER2- EBC to identify patients at high risk of recurrence
Joyce O'Shaughnessy
Integrating latest evidence and guideline recommendations to support multifactorial clinical decisions about use of adjuvant CDK4/6 inhibition in high-risk, HR+, HER2- EBC
Stephen Johnston
Mitigating adverse events, improving adherence/persistence, and maximizing treatment benefits from CDK4/6 inhibitors in high-risk, HR+, HER2- EBC
Patrick Neven
Q&A, synthesis, and conclusions
All Faculty

Table of Contents